基于维奈克拉的复发或难治性急性髓系白血病治疗：2022年美国血液学会年会的最新进展
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting.
作者信息
Gong Xubo, Zhang Yi, He Xin, Moloudizargari Milad, Yu Teng, Wang Lin, Liu Weiwei, Jin Lan, Xu Huiying, Xu Yang, Tao Zhihua, Qian Wenbin
机构信息
Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310000, Zheijang, P.R. China.
Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zheijang, P.R. China.
出版信息
Exp Hematol Oncol. 2023 Jun 30;12(1):57. doi: 10.1186/s40164-023-00424-z.
Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), while its role in relapsed or refractory (R/R) disease is not well defined. Here, we reviewed the latest advances of VEN-based therapy for R/R AML from the 2022 American Society of Hematology (ASH) Annual Meeting, including some novel and encouraging regimes, such as VCA, VAH, and HAM regimes, etc. Further research is still needed to fully understand the optimal use of these agents in R/R AML treatment.
维奈克拉（VEN）是首个选择性Bcl-2抑制剂，已显示出作为单药疗法以及与其他药物联合用于治疗新诊断急性髓系白血病（AML）时的有效性和安全性，而其在复发或难治性（R/R）疾病中的作用尚不明确。在此，我们回顾了2022年美国血液学会（ASH）年会中基于维奈克拉治疗R/R AML的最新进展，包括一些新颖且令人鼓舞的方案，如VCA、VAH和HAM方案等。仍需要进一步研究以充分了解这些药物在R/R AML治疗中的最佳使用方法。
Zotero 插件